A5074589634- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Cytomegalovirus and herpesvirus research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Mesenchymal stem cell research
- Transplantation: Methods and Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Neutropenia and Cancer Infections
- Eosinophilic Disorders and Syndromes
- Virus-based gene therapy research
- Hematological disorders and diagnostics
- Childhood Cancer Survivors' Quality of Life
- T-cell and Retrovirus Studies
Duke Cancer Institute
2020-2025
Duke University
1937-2025
Duke Medical Center
1960-2025
Dana-Farber Cancer Institute
2014-2023
Harvard University
2013-2023
Cancer Institute (WIA)
2021
Brigham and Women's Hospital
2009-2020
Dana-Farber Brigham Cancer Center
2006-2018
Fred Hutch Cancer Center
2017
Cancer Research Center
2017
Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance vivo suppress clinical manifestations GVHD.
Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival (OS) compared myeloablative (MAC). To test this hypothesis, we performed a phase III randomized trial comparing MAC RIC patients acute myeloid leukemia or myelodysplastic syndromes. Patients and Methods age 18 to 65 years HCT comorbidity...
Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse hematologic cancers. We hypothesized that checkpoint blockade established by targeting cytotoxic T-lymphocyte–associated protein 4 with ipilimumab could restore reactivity through a graft-versus-tumor effect.
Regulatory T cell homeostasis is restored in patients with chronic graft-versus-host disease who receive low-dose interleukin-2 therapy.
Purpose Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by somatic mutations in the blood otherwise healthy adults. We hypothesized that patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at time ASCT would be associated with increased risk myelodysplastic syndrome and acute myeloid leukemia, collectively termed therapy-related neoplasm (TMN), other adverse outcomes. Methods performed whole-exome sequencing on...
Recurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic drivers and powerfully associated with clinical phenotype prognosis. Whether these types of mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) patients MDS is not known.We used massively parallel sequencing to examine tumor samples collected from 87 before HSCT for coding 40 recurrently genes.Mutations were identified 92% patients, most frequently the ASXL1 (29%), TP53 (21%),...
PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) status before alloHCT has been shown to be prognostic. Whether modulation of the intensity conditioning regimen patients who test positive MRD can prevent and improve survival is unknown. METHODS Ultra-deep, error-corrected sequencing 13 commonly mutated genes was performed on preconditioning blood...
Umbilical cord blood (UBC) stem cells are a useful cell source for patients without matched related or unrelated donors. Adult transplantation with single UBC units is associated high transplantation-related mortality (TRM). In most cases, due to infection slow engraftment and immunoincompetence. this study, we used reduced-intensity conditioning regimen of fludarabine, melphalan, antithymocyte globulin followed by 2 partially units. The were 4/6 HLA match better each other the patient...
Purpose Several open-label randomized studies have suggested that in vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovii Biotech, Lexington, MA) on cGVHD-free Patients and Methods Two hundred fifty-four patients 18 65 years age acute leukemia or myelodysplastic...
CD4+CD25+Foxp3+ Tregs have an indispensable role in the maintenance of tolerance after allogeneic HSC transplantation (HSCT). Patients with chronic graft-versus-host disease (GVHD) fewer circulating Tregs, but mechanisms that lead to this deficiency HSCT are not known. Here, we analyzed reconstitution and conventional CD4+ T cells (Tcons) patients who underwent myeloablative conditioning. Following transplant, thymic generation naive was markedly impaired, reconstituting had a predominantly...